Why ischemic stroke patients do not receive thrombolytic treatment: Results from a general hospital

Acta Neurologica Scandinavica

Volumn 120, Issue 3, 2009, Pages 157-160

  Van Den Berg, J S P ^a   De Jong, G ^a  

^a Isala Klinieken ^*  (Netherlands)

Author keywords

Intravenous thrombolysis; Ischemic stroke; Outcome

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE REGISTRY; DRUG INDICATION; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; GENERAL HOSPITAL; HEALTH PROMOTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT SELECTION; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; BRAIN INFARCTION; EMERGENCY SERVICE, HOSPITAL; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 69249189814     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01140.x     Document Type: Article

References (13)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997 349 : 1436 1442.
2. Palmer AJ, Valentine WJ, Roze S, Lammert M, Spiesser J, Gabriel S. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. Curr Med Res Opin 2005 21 : 19 26.
3. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008 371 : 1612 1623.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995 333 : 1581 1587.
5. Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004 363 : 768 774.
6. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007 38 : 3055 3062.
7. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999 30 : 1538 1541.
8. Wilson JT, Hareendran A, Grant M et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002 33 : 2243 2246.
9. Vergouwen MD, Kwa VI, Weinstein HC, Imanse JG, Visser MC, Stam J. Trombolyse bij acute herseninfarcten - implementatie van een nieuwe therapie. Tijdschr Neurol Neurochir 2007 108 : 57 62.
10. Boiten J, Wilmink JT, Lodder J, Troost J. Thrombolytic therapy in patients with acute brain infarction: favorable preliminary results in Maastricht. Ned Tijdschr Geneeskd 2000 144 : 1062 1069.
11. Dirks M, Niessen LW, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, Dippel DW. Delphi panel on indications and contraindications for intravenous thrombolysis in acute ischaemic stroke. Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study. J Neurol Neurosurg Psychiatry 2007 78 : 685 689.
12. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001 56 : 1015 1020.
13. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 2008 39 : 1774 1778.